002422 科伦药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)8.57613.87411.5268.0616.216
总资产报酬率 ROA (%)4.8336.9525.1883.4712.614
投入资产回报率 ROIC (%)6.3428.9576.6214.3573.332

边际利润分析
销售毛利率 (%)53.83252.43052.51655.66454.247
营业利润率 (%)24.62117.03311.5307.6396.134
息税前利润/营业总收入 (%)24.45617.77913.3829.7439.399
净利润/营业总收入 (%)18.73512.3368.9525.0254.807

收益指标分析
经营活动净收益/利润总额(%)90.45688.72087.75683.80775.268
价值变动净收益/利润总额(%)7.65210.43311.82118.6539.973
营业外收支净额/利润总额(%)-1.636-2.059-6.152-12.078-5.752

偿债能力分析
流动比率 (X)1.9651.8301.3761.0451.199
速动比率 (X)1.6281.4461.1100.7940.916
资产负债率 (%)31.83336.86650.67855.2010.562
带息债务/全部投入资本 (%)18.12127.32439.04042.21345.204
股东权益/带息债务 (%)430.412255.616151.090132.162115.874
股东权益/负债合计 (%)184.205146.37990.76679.58975.078
利息保障倍数 (X)105.77816.3175.3103.3292.612

营运能力分析
应收账款周转天数 (天)71.52487.082103.975114.391132.940
存货周转天数 (天)116.849124.413130.958160.520163.786